HK Stock Movement | CARSGEN-B (02171) Rises Nearly 4%, Recently Announced Collaboration with Dispatch Bio to Plan Related Clinical Trials for CT053

Stock News11:18

CARSGEN-B (02171) rose nearly 4%, and as of the time of writing, it was up 3.96%, trading at HK$16.27 with a turnover of HK$4.9417 million. Recently, according to a post on the company's official social media account, CARSGEN announced it has entered into a clinical collaboration with Dispatch Bio, a biotechnology firm leveraging its first-in-class Flare platform to develop off-the-shelf treatments for solid tumors. The collaboration plans to initiate a Phase I clinical trial in China by 2026. This trial will evaluate the combination therapy DISP-11 in patients with solid tumors. Reportedly, this combination therapy consists of an investigational treatment developed using Dispatch's pioneering Flare platform, which includes its novel tumor-specific virus DV-10, used in conjunction with CARSGEN's BCMA-targeted autologous CAR-T cell product, CT053 (Zevor-cel injection). CT053 has already received approval from China's National Medical Products Administration (NMPA) for the treatment of multiple myeloma.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1176768425?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-22 11:18","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1176768425","market":"sg","top_or_hot":-1,"title":"HK Stock Movement | CARSGEN-B (02171) Rises Nearly 4%, Recently Announced Collaboration with Dispatch Bio to Plan Related Clinical Trials for CT053","media":"Stock News","content":"<p>CARSGEN-B (02171) rose nearly 4%, and as of the time of writing, it was up 3.96%, trading at HK$16.27 with a turnover of HK$4.9417 million.\nRecently, according to a post on the company's official social media account, CARSGEN announced it has entered into a clinical collaboration with Dispatch Bio, a biotechnology firm leveraging its first-in-class Flare platform to develop off-the-shelf treatments for solid tumors.\nThe collaboration plans to initiate a Phase I clinical trial in China by 2026.\nThis trial will evaluate the combination therapy DISP-11 in patients with solid tumors.\nReportedly, this combination therapy consists of an investigational treatment developed using Dispatch's pioneering Flare platform, which includes its novel tumor-specific virus DV-10, used in conjunction with CARSGEN's BCMA-targeted autologous CAR-T cell product, CT053 (Zevor-cel injection).\nCT053 has already received approval from China's National Medical Products Administration (NMPA) for the treatment of multiple myeloma.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>HK Stock Movement | CARSGEN-B (02171) Rises Nearly 4%, Recently Announced Collaboration with Dispatch Bio to Plan Related Clinical Trials for CT053</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHK Stock Movement | CARSGEN-B (02171) Rises Nearly 4%, Recently Announced Collaboration with Dispatch Bio to Plan Related Clinical Trials for CT053\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-01-22 11:18</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>CARSGEN-B (02171) rose nearly 4%, and as of the time of writing, it was up 3.96%, trading at HK$16.27 with a turnover of HK$4.9417 million.\nRecently, according to a post on the company's official social media account, CARSGEN announced it has entered into a clinical collaboration with Dispatch Bio, a biotechnology firm leveraging its first-in-class Flare platform to develop off-the-shelf treatments for solid tumors.\nThe collaboration plans to initiate a Phase I clinical trial in China by 2026.\nThis trial will evaluate the combination therapy DISP-11 in patients with solid tumors.\nReportedly, this combination therapy consists of an investigational treatment developed using Dispatch's pioneering Flare platform, which includes its novel tumor-specific virus DV-10, used in conjunction with CARSGEN's BCMA-targeted autologous CAR-T cell product, CT053 (Zevor-cel injection).\nCT053 has already received approval from China's National Medical Products Administration (NMPA) for the treatment of multiple myeloma.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02800","symbol_name":"盈富基金","start_time":0,"source_url":"","article_id":"1176768425","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1176768425","pubTimestamp":1769051898,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"CARSGEN-B (02171) rose nearly 4%, and as of the time of writing, it was up 3.96%, trading at HK$16.27 with a turnover of HK$4.9417 million. Recently, according to a post on the company's official...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02800":"盈富基金","BK1161":"生物科技","BK1610":"ETF&股票定投概念","02171":"科济药业-B","BK1587":"次新股","BK1574":"生物医药B类股","BK1585":"昨日强势股"},"translate_title":"港股动向|科济生物-B(02171)涨近4%，近日宣布与Dispatch Bio合作筹划CT053相关临床试验","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02800":1,"02171":1},"content_text":"CARSGEN-B (02171) rose nearly 4%, and as of the time of writing, it was up 3.96%, trading at HK$16.27 with a turnover of HK$4.9417 million.\nRecently, according to a post on the company's official social media account, CARSGEN announced it has entered into a clinical collaboration with Dispatch Bio, a biotechnology firm leveraging its first-in-class Flare platform to develop off-the-shelf treatments for solid tumors.\nThe collaboration plans to initiate a Phase I clinical trial in China by 2026.\nThis trial will evaluate the combination therapy DISP-11 in patients with solid tumors.\nReportedly, this combination therapy consists of an investigational treatment developed using Dispatch's pioneering Flare platform, which includes its novel tumor-specific virus DV-10, used in conjunction with CARSGEN's BCMA-targeted autologous CAR-T cell product, CT053 (Zevor-cel injection).\nCT053 has already received approval from China's National Medical Products Administration (NMPA) for the treatment of multiple myeloma.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1176768425","isCrawlerRequest":true}